liverpool skyline

Our research

Our research aims to provide a real-world impact in the treatment of patients, by providing novel tools to clinicians aiding them to properly diagnose and treat illness.

A recent prospective observational study by researchers in the DynAIRx team was undertaken at Liverpool University Hospitals NHS Foundation Trust and has identified a rising tide of medication-related harm, increasing from 6.5% in 2004 to 16.5% of admissions being caused by, or complicated by, an adverse reaction to a medicine.

The NHS introduced structured medication reviews by GPs and pharmacists to reduce the number of people taking potentially harmful combinations of drugs. However, there is no easy way of predicting which patients are most likely to benefit from a medication review and prioritising them.

DynAIRx is developing tools to combine information from electronic health and social care records, clinical guidelines and risk-prediction models to ensure that clinicians and patients have the best information to prioritise and support structured medication reviews.

The team is developing artificial intelligence (AI) that combine information from multiple records and guidelines and calculate risks of hospital admissions and other adverse outcomes for our three multimorbidity groups.

To ensure this information is easily understandable we are developing visual summaries of patients’ journeys, showing how health conditions, treatments and risks of future adverse outcomes are changing over time. These visual summaries will be tested in general practices across northern England and improved based on feedback from clinicians and patients. The DynAIRx study have published our project protocol in the Journal of Multimorbidity and Comorbidity. 

The DynAIRx project will utilise artificial intelligence technologies to help us develop new tools and procedures for GPs to better treat patients, prescribe medication, and understand illness. We are confident this can deliver better outcomes, with a more effective care pathway.

Professor Iain Buchan

Back to: Dynairx